Abstract:Background: The RNA N6-methyladenosine (m6A) modification has become an essential hotspot in epigenetic modulation. Serine-arginine protein kinase 1 (SRPK1) is associated with the pathogenesis of various cancers. However, the m6A modification of SRPK1 and its association with the mechanism of in lung adenocarcinoma (LUAD) remains unclear. Methods: Western blotting and polymerase chain reaction (PCR) analyses were carried out to identify gene and protein expression. m6A epitranscriptomic microarray was utilized to the assess m6A profile. Loss and gain-of-function assays were carried out elucidate the impact of METTL3 and SRPK1 on LUAD glycolysis and tumorigenesis. RNA immunoprecipitation (RIP), m6A RNA immunoprecipitation (MeRIP), and RNA stability tests were employed to elucidate the SRPK1's METTL3-mediated m6A modification mechanism in LUAD. Metabolic quantification and co-immunoprecipitation assays were applied to investigate the molecular mechanism by which SRPK1 mediates LUAD metabolism. Results: The epitranscriptomic microarray assay revealed that SRPK1 could be hypermethylated and upregulated in LUAD. The main transmethylase METTL3 was upregulated and induced the aberrant high m6A levels of SRPK1. Mechanistically, SRPK1's m6A sites were directly methylated by METTL3, which also stabilized SRPK1 in an IGF2BP2-dependent manner. Methylated SRPK1 subsequently promoted LUAD progression through enhancing glycolysis. Further metabolic quantification, co-immunoprecipitation and western blot assays revealed that SRPK1 interacts with hnRNPA1, an important modulator of PKM splicing, and thus facilitates glycolysis by upregulating PKM2 in LUAD. Nevertheless, METTL3 inhibitor STM2457 can reverse the above effects in vitro and in vivo by suppressing SRPK1 and glycolysis in LUAD. Conclusion: It was revealed that in LUAD, aberrantly expressed METTL3 upregulated SRPK1 levels via an m6A-IGF2BP2-dependent mechanism. METTL3-induced SRPK1 fostered LUAD cell proliferation by enhancing glycolysis, and the small-molecule inhibitor STM2457 of METTL3 could be an alternative novel therapeutic strategy for individuals with LUAD.

N6-methyladenosine in 7SK Small Nuclear RNA Underlies RNA Polymerase II Transcription Regulation.

N 6 -methyladenosine in 7SK small nuclear RNA underlies RNA polymerase II transcription regulation

Retraction Note: RNA M6a Methylation Regulates the Epithelial Mesenchymal Transition of Cancer Cells and Translation of Snail.

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

The emerging roles of N6-methyladenosine RNA methylation in human cancers

Rna N-6-Methyladenosine Methylation In Post-Transcriptional Gene Expression Regulation

The Roles of M6a RNA Modifiers in Human Cancer

The roles of m<SUP>6</SUP>A RNA modifiers in human cancer

N 6 ‐methyladenosine Steers RNA Metabolism and Regulation in Cancer

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

A positive feedback circuit between RN7SK snRNA and m6A readers is essential for tumorigenesis

N6-Methyladenosine: A Novel RNA Imprint in Human Cancer

N6-methyladenosine Modification: an Important Player in the Tumor Immune Microenvironment.

N-6-Methyladenosine: A Novel RNA Imprint in Human Cancer

RNA N6-Methyladenine Modification, Cellular Reprogramming, and Cancer Stemness

N6 -Methyladenosine Regulates mRNA Stability and Translation Efficiency of KRT7 to Promote Breast Cancer Lung Metastasis

RNA M6a Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications.

Emerging roles of the crosstalk between non-coding RNAs and m<SUP>6</SUP>A modification in cancers

Regulation of Telomere Homeostasis and Genomic Stability in Cancer by N6-adenosine Methylation (M6a)

RNA N6-methyladenosine Modification Mediates Downregulation of NR4A1 to Facilitate Malignancy of Cervical Cancer.

N6-methyladenosine-modified SRPK1 promotes aerobic glycolysis of lung adenocarcinoma via PKM splicing